Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04570488 · ClinicalTrials.gov registry record
Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 1,415
- Enrollment target
NCT04570488 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 1,415 participants.
The verdict
NCT04570488 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 1,415 participants
- Enrollment target
Study Summary
Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours
Interventions
- OTHER EPIC risk score display
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2020-05-15 |
| Est. Completion | 2021-12-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04570488
The ClinicalTrials.gov registry entry for NCT04570488 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EPIC risk score display is the first listed.
NCT04570488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04570488 about?
NCT04570488 is a clinical study titled "Predicting Favorable Outcomes in Hospitalized Covid-19 Patients". Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours
What is the current status of trial NCT04570488?
This trial is currently completed. The enrollment target is 1,415 participants. The study started on 2020-05-15. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04570488?
The interventions under investigation include: EPIC risk score display (OTHER).
Who is sponsoring clinical trial NCT04570488?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.